Overview

Pain Biomarker Study

Status:
Active, not recruiting
Trial end date:
2022-05-31
Target enrollment:
0
Participant gender:
All
Summary
This study investigates molecular and physical biomarkers of headaches in order to better understand mechanisms of these diseases. There are 3 main parts: 1. Use of capsaicin (active ingredient in hot chili peppers) to trigger release of calcitonin gene related peptide - the hypothesis is that this will be different in headache subjects compared to controls (and if so might be used to predict how these patients will respond to certain medications that modulate calcitonin gene-related peptide). Subjects will be given capsaicin as a cream applied to the forehead or the inner nostril, or a hot sauce that is ingested. 2. Use of capsaicin to trigger eye watering - the hypothesis is that oxygen gas will slow down the amount of eye watering. Cluster headache patients respond very powerfully to oxygen gas but to very little else. The mechanism for oxygen is unknown but in rodents there is data that it works on the parasympathetic / lacrimal gland system. This study translates rodent data into humans in a non-invasive way to confirm the mechanism of this very effective treatment. 3. Use of ice water to trigger headaches - brain freeze causes a very short-lived but intense headache that may cause similar biomarker release as other headache disorders. This may be a useful human model for other headache disorders.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston
Collaborator:
University of California, San Francisco
Treatments:
Capsaicin
Criteria
Inclusion Criteria:

- Diagnosis of one of the following: a. Diagnosis of a primary headache disorder
according to the International Headache Classification, including migraine with aura,
migraine without aura, chronic migraine, tension headache, cluster headache,
paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks with
conjunctival injection and tearing (SUNCT), short-lasting unilateral neuralgiform
headache attacks with cranial autonomic symptoms (SUNA), and hemicrania continua; b.
Diagnosed by a pain medicine physician with lumbar radiculopathy (possibly including
neuropathic features, nerve impingement on MRI, or electromyography (EMG) report
suggestive of lumbar radiculopathy); or c. Healthy control subject with no history of
debilitating headaches or debilitating back pain / radiculopathy pain, and no
headaches or back pain within the previous 3 months.

- Able to provide HIPAA authorization to share prior medical records/imaging

- Age 18 and older

Exclusion Criteria:

- The following items exclude the subject from all portions of the study: a. Known
history of cardiovascular or neurovascular diseases. These diseases may include
carotid stenosis of >50%, vertebral stenosis, peripheral vascular disease, angina or
myocardial infarction, stroke, or vascular malformations; b. History of brain tumors
or epilepsy; c. Active pregnancy or lactation; d. Daily cigarette, tobacco or nicotine
use; e. Life expectancy less than 1 year, co-existing disease or other characteristic
that precludes appropriate diagnosis of headache or spine pain; f. Active drug /
alcohol use or dependence that, in the opinion of the investigator, would interfere
with adherence to study requirements; or g. Inability or unwillingness of subject to
give informed consent (e.g., ward of the state)

- The following items exclude the subject only from the capsaicin portion of the study:
a. Known allergy to capsaicin or hot peppers

- The following items exclude the subject only from the oxygen portion of the study: a.
Pulmonary or other non-headache diseases that require the use of supplemental oxygen

- The following items exclude the subject only from the cold water irrigation (ice
water) portion of the study: a. Trauma, fractures, or congenital abnormalities of the
soft palate